ArticleScientific reports2026
Low intensity vibration as a novel strategy to normalize age-related deficits in T cell proliferation, activation, and function.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Age related decline in number, activation, and function of T lymphocytes are hallmarks of immune dysfunction. Exercise is often described as the single best intervention to protect and promote robust immune function during aging. While these benefits are often presumed to be an indirect byproduct of increased metabolism, exercise may also deliver a direct benefit to the immune cell through its innate sensitivity to mechanical signals. We tested the hypothesis that mechanical stimulation, delivered non-invasively using low intensity vibration (LIV, at: 2 h of 30 Hz, 0.7 g) could augment T cell expansion without disrupting their phenotype, as well as improve the status of aged, dysfunctional, T cells. As compared to sham-handled controls, LIV increased proliferation 59% in T cells isolated from elderly patients (69.3y ± 2.6) while increasing expansion by only 13% in T cells harvested from young subjects (22.7y ± 3.8). T cell activation and production of pro-inflammatory cytokines (e.g., IL-2 by + 25%; p < 0.05) were also increased by LIV. Exploring whether this in vitro influence could translate to an in vivo model of aging, 4w of 30 min/d of LIV applied to 18-month-old mice resulted in significant increases in T cell activation as compared to sham-handled controls (102% increase in CD25 & 44.2% increase in CD69; p < 0.05). LIV also improved T cell anti-viral functionality, as 18-month-old mice pre-treated with 4w of LIV prior to infection with an Influenza A virus exhibited 18% less weight loss at 12d compared to sham-handled controls, a critical indication of a more robust immune system. These data suggest that extremely low magnitude mechanical signals, introduced non-invasively using LIV, represent a novel, non-drug therapeutic strategy for ameliorating age-related declines in immune function.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.